Evidence map›Paper›PMID 12364999›Full record

ReviewGene therapy2002

Gene therapy progress and prospects: cystic fibrosis.

U Griesenbach, S Ferrari, D M Geddes, E W F W Alton

Abstract readReview
In one paragraph

Review in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Progress in Respiratory Gene Therapy.Human gene therapy · 2022
    Review
  2. Review
  3. Review
  4. Article
  5. Nanoparticle deposition onto biofilms.Annals of biomedical engineering · 2013
    Article
  6. Article
  7. Gene therapy for the treatment of cystic fibrosis.The application of clinical genetics · 2012
    Article
  8. Article
  9. Article
  10. Sensitivity of chloride efflux vs. transepithelial measurements in mixed CF and normal airway epithelial cell populations.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2010
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

U GriesenbachDepartment of Gene Therapy, National Heart and Lung Institute, Imperial College, Faculty of Medicine, London, UK.
S Ferrari
D M Geddes
E W F W Alton

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer agents (adenovirus (Ad), adeno-associated virus 2 (AAV2) and cationic liposomes) was low, and most likely insufficient to achieve clinical benefit. Here, we will review the clinical and pre-clinical progress for the last 2 years (2000-2001) and briefly speculate on future prospects for the next 2 in CF gene therapy.

Indexed as

AnimalsClinical Trials, Phase I as TopicCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorEpithelial CellsGene ExpressionGene TargetingGenetic TherapyGenetic VectorsGene Transfer TechniquesHumansLungOligonucleotides, AntisenseCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorOligonucleotides, Antisense

Identifiers

PMID12364999
PMCPMC7091818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.